|
|
Article: IMPAX Receives Final FDA Approval for Generic Xanax(R) XR Extended Release Tablets.
- Article from:
- Business Wire
- Article date:
- May 29, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
-Global Pharmaceuticals Division to Launch-
HAYWARD, Calif. -- IMPAX Laboratories, Inc. (OTC:IPXL) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company's Abbreviated New Drug Application (ANDA) for generic versions of Xanax[R] XR, (Alprazolam) 0.5 mg, 1 mg, 2 mg and 3 mg Extended-release Tablets. Pharmacia and Upjohn markets Xanax XR for the management of anxiety disorder or the short-term relief of symptoms of anxiety. IMPAX' Global Pharmaceuticals division plans to launch the product soon.
U.S. sales of the combined branded and generic 0.5 mg, 1 mg, 2 mg and 3 mg dosage forms were approximately $51 ...